vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and LAKELAND FINANCIAL CORP (LKFN). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $69.7M, roughly 1.2× LAKELAND FINANCIAL CORP). LAKELAND FINANCIAL CORP runs the higher net margin — 38.0% vs 22.8%, a 15.2% gap on every dollar of revenue. Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 0.7%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Amscot Financial is an American financial services company headquartered in Tampa, Florida. Founded in 1989 by Ian MacKechnie, Amscot Financial provides non-bank consumer financial services through a network of retail branches located exclusively within Florida. Amscot's core services include check cashing, bill payment, prepaid access cards, payday loans, free money orders, ATMs in every branch, wire transfers, notary services, fax services, and postage. Amscot Financial operates nearly 240 ...

FDMT vs LKFN — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.2× larger
FDMT
$85.1M
$69.7M
LKFN
Higher net margin
LKFN
LKFN
15.2% more per $
LKFN
38.0%
22.8%
FDMT
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
0.7%
LKFN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FDMT
FDMT
LKFN
LKFN
Revenue
$85.1M
$69.7M
Net Profit
$19.4M
$26.5M
Gross Margin
Operating Margin
17.3%
Net Margin
22.8%
38.0%
Revenue YoY
8508900.0%
Net Profit YoY
139.1%
31.8%
EPS (diluted)
$0.43
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
LKFN
LKFN
Q1 26
$69.7M
Q4 25
$85.1M
$69.8M
Q3 25
$90.0K
$69.0M
Q2 25
$15.0K
$66.4M
Q1 25
$14.0K
$63.8M
Q4 24
$1.0K
$63.6M
Q3 24
$3.0K
$61.2M
Q2 24
$5.0K
$68.7M
Net Profit
FDMT
FDMT
LKFN
LKFN
Q1 26
$26.5M
Q4 25
$19.4M
$29.9M
Q3 25
$-56.9M
$26.4M
Q2 25
$-54.7M
$27.0M
Q1 25
$-48.0M
$20.1M
Q4 24
$24.2M
Q3 24
$-43.8M
$23.3M
Q2 24
$-35.0M
$22.5M
Operating Margin
FDMT
FDMT
LKFN
LKFN
Q1 26
Q4 25
17.3%
52.1%
Q3 25
-67983.3%
46.4%
Q2 25
-396373.3%
49.6%
Q1 25
-383007.1%
38.0%
Q4 24
46.0%
Q3 24
-1704400.0%
45.3%
Q2 24
-849120.0%
39.2%
Net Margin
FDMT
FDMT
LKFN
LKFN
Q1 26
38.0%
Q4 25
22.8%
42.8%
Q3 25
-63195.6%
38.3%
Q2 25
-364386.7%
40.6%
Q1 25
-342657.1%
31.5%
Q4 24
38.1%
Q3 24
-1461433.3%
38.1%
Q2 24
-699060.0%
32.8%
EPS (diluted)
FDMT
FDMT
LKFN
LKFN
Q1 26
$1.04
Q4 25
$0.43
$1.16
Q3 25
$-1.01
$1.03
Q2 25
$-0.98
$1.04
Q1 25
$-0.86
$0.78
Q4 24
$0.94
Q3 24
$-0.79
$0.91
Q2 24
$-0.63
$0.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
LKFN
LKFN
Cash + ST InvestmentsLiquidity on hand
$402.7M
$85.6M
Total DebtLower is stronger
$183.6M
Stockholders' EquityBook value
$505.7M
$749.0M
Total Assets
$566.7M
$7.1B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
LKFN
LKFN
Q1 26
$85.6M
Q4 25
$402.7M
$141.3M
Q3 25
$305.1M
$192.8M
Q2 25
$293.2M
$310.2M
Q1 25
$321.4M
$235.2M
Q4 24
$424.9M
$168.2M
Q3 24
$501.9M
$160.2M
Q2 24
$541.9M
$121.2M
Total Debt
FDMT
FDMT
LKFN
LKFN
Q1 26
$183.6M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$30.0M
Q2 24
$55.0M
Stockholders' Equity
FDMT
FDMT
LKFN
LKFN
Q1 26
$749.0M
Q4 25
$505.7M
$762.4M
Q3 25
$369.0M
$747.4M
Q2 25
$420.9M
$709.9M
Q1 25
$469.7M
$694.4M
Q4 24
$510.6M
$683.8M
Q3 24
$552.9M
$699.1M
Q2 24
$588.3M
$654.5M
Total Assets
FDMT
FDMT
LKFN
LKFN
Q1 26
$7.1B
Q4 25
$566.7M
$7.0B
Q3 25
$424.0M
$6.9B
Q2 25
$473.6M
$7.0B
Q1 25
$515.7M
$6.9B
Q4 24
$560.4M
$6.7B
Q3 24
$604.0M
$6.6B
Q2 24
$620.1M
$6.6B
Debt / Equity
FDMT
FDMT
LKFN
LKFN
Q1 26
0.25×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.04×
Q2 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
LKFN
LKFN
Operating Cash FlowLast quarter
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
LKFN
LKFN
Q1 26
Q4 25
$28.6M
$114.9M
Q3 25
$-46.5M
$36.1M
Q2 25
$-43.4M
$16.2M
Q1 25
$-47.8M
$28.9M
Q4 24
$-134.6M
$102.5M
Q3 24
$-29.4M
$18.0M
Q2 24
$-30.2M
$21.0M
Free Cash Flow
FDMT
FDMT
LKFN
LKFN
Q1 26
Q4 25
$28.5M
$103.8M
Q3 25
$-46.6M
$31.1M
Q2 25
$-43.4M
$14.1M
Q1 25
$-48.4M
$27.1M
Q4 24
$-138.4M
$93.9M
Q3 24
$-31.2M
$15.3M
Q2 24
$-30.6M
$18.6M
FCF Margin
FDMT
FDMT
LKFN
LKFN
Q1 26
Q4 25
33.5%
148.7%
Q3 25
-51765.6%
45.0%
Q2 25
-289620.0%
21.2%
Q1 25
-345635.7%
42.5%
Q4 24
-13837100.0%
147.6%
Q3 24
-1038966.7%
25.0%
Q2 24
-611840.0%
27.0%
Capex Intensity
FDMT
FDMT
LKFN
LKFN
Q1 26
Q4 25
0.1%
15.9%
Q3 25
101.1%
7.3%
Q2 25
440.0%
3.2%
Q1 25
4507.1%
2.8%
Q4 24
378600.0%
13.6%
Q3 24
59266.7%
4.4%
Q2 24
6980.0%
3.5%
Cash Conversion
FDMT
FDMT
LKFN
LKFN
Q1 26
Q4 25
1.47×
3.84×
Q3 25
1.37×
Q2 25
0.60×
Q1 25
1.44×
Q4 24
4.24×
Q3 24
0.77×
Q2 24
0.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

LKFN
LKFN

Net Interest Income$56.8M81%
Noninterest Income$12.9M19%

Related Comparisons